FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2553001558> ?p ?o ?g. }

• W2553001558 abstract "Abstract Abstract 2618 Poster Board II-594 AML with mutated nucleophosmin (NPM1) is a provisional entity in the WHO-2008 classification of myeloid neoplasms. A yet unresolved issue concerning NPM1-mutated AML is the biological and clinical significance of concomitant multilineage dysplasia (MLD). So far, NPM1+ AML with MLD is classified as AML with myelodysplasia-related changes in the new WHO classification. Therefore, we addressed the impact of MLD in 378 de novo AML patients with mutated/cytoplasmic NPM1 and performed comparison of cytomorphological features, cytogenetics, the FLT3 mutation status, and gene expression profiles in patients with and without MLD. MLD - as defined by dysplastic features in at least two hematopoietic lineages by cytomorphology - was present in 95/378 (25.1%) cases. Mean age (±standard deviation) was 52.1±14.0 years in the group with MLD and 54.8±14.5 in the group without MLD (p=0.11). Males comprised 50/95 (52.6%) in the group with MLD vs. 119/283 (42%) in the group without MLD (p=0.075). Morphological subtypes according to FAB/WHO were available in 365 cases (96.5%) and did not differ significantly between both groups. The median WBC was 17.1 G/l (range: 0.9–211.0 G/l) in the group with MLD and 35.6 G/l (range: 0.5–600.0 G/l) in the group without MLD (p=0.0027). Absence of CD34 expression was observed in 60/74 (81.1%) and 172/212 (81.1%) cases of the groups with and without MLD, respectively (p=1.0). Cytogenetic data was available in all 378 cases: An abnormal karyotype was present in 15/95 (15.8%) cases with MLD and in 37/283 (13.1%) cases without MLD (p=0.49). Molecular analyses detected the FLT3-ITD in 16/91 (17.6%) cases tested with MLD and in 110/276 (39.9%) cases without MLD (p<0.001). FLT3-TKD mutations were found in 7/80 (8.8%) patients within the group with MLD and in 21/221 (9.5%) patients within the group without MLD, respectively (p=1.0). Moreover, NPM1-mutated AML with or without MLD demonstrated non-discriminative microarray gene expression profiles (Affymetrix HG-U133 Plus 2.0). The gene expression profiles, however, clearly differed between NPM1-mutated AML and NPM1-wildtype cases as control group, e.g. by detectable downregulation of CD34 and upregulation of the characteristic HOX gene signature. This indicates that NPM1 mutations rather than MLD dictate the distinctive features of this AML subtype. With respect to clinical relevance, presence of MLD had no significant influence on overall survival (OS), however, it was related to a better event-free survival (EFS, median 33.3 vs. 13.9 months, p=0.0412), which is likely due to the fact that FLT3-ITD were less common in the MLD+ group (p=0.001). In addition also in our cohort the presence of an FLT3-ITD was associated with a significantly shorter EFS (median 11.2 vs. 22.3 months, p=0.0002) and a significantly shorter OS (median 12.5 months vs. not reached, p<0.0001). MLD also had no impact on outcome if analyzed within the groups with or without FLT3-ITD, respectively. Multivariate analysis revealed FLT3-ITD as the only parameter independently related to EFS (p=0.0051) and OS (p=0.0024). In conclusion, the discrimination of AML with MLD from AML without MLD in NPM1-mutated AML does not lead to distinct entities of AML since biologic features and outcome are largely similar. The FLT3-ITD mutation, however, again was confirmed to be an important biological parameter in AML with NPM1 mutations as demonstrated by a significantly worse outcome. Thus, our data underlines that NPM1+ AML is a distinct entity and further suggests that NPM1+ AML should be considered as one group irrespective of the presence or absence of MLD. Disclosures: Haferlach: MLL Munich Leukemia Laboratory: Equity Ownership. Macijewski:MLL Munich Leukemia Laboratory: Employment. Weiss:MLL Munich Leukemia Laboratory: Employment. Schnittger:MLL Munich Leukemia Laboratory: Equity Ownership. Kern:MLL Munich Leukemia Laboratory: Equity Ownership. Kohlmann:MLL Munich Leukemia Laboratory: Employment. Miesner:MLL Munich Leukemia Laboratory: Employment. Haferlach:MLL Munich Leukemia Laboratory: Equity Ownership. Falini:Xenomics: Patents & Royalties." @default.
• W2553001558 created "2016-11-30" @default.
• W2553001558 creator A5001737873 @default.
• W2553001558 creator A5003682222 @default.
• W2553001558 creator A5008077055 @default.
• W2553001558 creator A5009095647 @default.
• W2553001558 creator A5009594855 @default.
• W2553001558 creator A5016635620 @default.
• W2553001558 creator A5021480569 @default.
• W2553001558 creator A5023137678 @default.
• W2553001558 creator A5041966654 @default.
• W2553001558 creator A5042691658 @default.
• W2553001558 creator A5043414993 @default.
• W2553001558 creator A5043985252 @default.
• W2553001558 creator A5048388170 @default.
• W2553001558 creator A5050041262 @default.
• W2553001558 creator A5053813643 @default.
• W2553001558 creator A5070043884 @default.
• W2553001558 creator A5078192708 @default.
• W2553001558 creator A5080931970 @default.
• W2553001558 creator A5085145776 @default.
• W2553001558 date "2009-11-20" @default.
• W2553001558 modified "2023-09-28" @default.
• W2553001558 title "The Presence of Multilineage Dysplasia (MLD) Has No Significant Impact On Biological, Clinico-Pathological, and Prognostic Features in AML with Mutated Nucleophosmin (NPM1)." @default.
• W2553001558 doi "https://doi.org/10.1182/blood.v114.22.2618.2618" @default.
• W2553001558 hasPublicationYear "2009" @default.
• W2553001558 type Work @default.
• W2553001558 sameAs 2553001558 @default.
• W2553001558 citedByCount "0" @default.
• W2553001558 crossrefType "journal-article" @default.
• W2553001558 hasAuthorship W2553001558A5001737873 @default.
• W2553001558 hasAuthorship W2553001558A5003682222 @default.
• W2553001558 hasAuthorship W2553001558A5008077055 @default.
• W2553001558 hasAuthorship W2553001558A5009095647 @default.
• W2553001558 hasAuthorship W2553001558A5009594855 @default.
• W2553001558 hasAuthorship W2553001558A5016635620 @default.
• W2553001558 hasAuthorship W2553001558A5021480569 @default.
• W2553001558 hasAuthorship W2553001558A5023137678 @default.
• W2553001558 hasAuthorship W2553001558A5041966654 @default.
• W2553001558 hasAuthorship W2553001558A5042691658 @default.
• W2553001558 hasAuthorship W2553001558A5043414993 @default.
• W2553001558 hasAuthorship W2553001558A5043985252 @default.
• W2553001558 hasAuthorship W2553001558A5048388170 @default.
• W2553001558 hasAuthorship W2553001558A5050041262 @default.
• W2553001558 hasAuthorship W2553001558A5053813643 @default.
• W2553001558 hasAuthorship W2553001558A5070043884 @default.
• W2553001558 hasAuthorship W2553001558A5078192708 @default.
• W2553001558 hasAuthorship W2553001558A5080931970 @default.
• W2553001558 hasAuthorship W2553001558A5085145776 @default.
• W2553001558 hasConcept C10205521 @default.
• W2553001558 hasConcept C104317684 @default.
• W2553001558 hasConcept C126322002 @default.
• W2553001558 hasConcept C142724271 @default.
• W2553001558 hasConcept C143998085 @default.
• W2553001558 hasConcept C174475383 @default.
• W2553001558 hasConcept C2483381 @default.
• W2553001558 hasConcept C2775894508 @default.
• W2553001558 hasConcept C2778729363 @default.
• W2553001558 hasConcept C2779282312 @default.
• W2553001558 hasConcept C2779384505 @default.
• W2553001558 hasConcept C2780007613 @default.
• W2553001558 hasConcept C2780817109 @default.
• W2553001558 hasConcept C28328180 @default.
• W2553001558 hasConcept C2908722627 @default.
• W2553001558 hasConcept C2994225774 @default.
• W2553001558 hasConcept C30481170 @default.
• W2553001558 hasConcept C45091340 @default.
• W2553001558 hasConcept C501734568 @default.
• W2553001558 hasConcept C53226629 @default.
• W2553001558 hasConcept C54355233 @default.
• W2553001558 hasConcept C63363279 @default.
• W2553001558 hasConcept C71924100 @default.
• W2553001558 hasConcept C86803240 @default.
• W2553001558 hasConcept C90924648 @default.
• W2553001558 hasConceptScore W2553001558C10205521 @default.
• W2553001558 hasConceptScore W2553001558C104317684 @default.
• W2553001558 hasConceptScore W2553001558C126322002 @default.
• W2553001558 hasConceptScore W2553001558C142724271 @default.
• W2553001558 hasConceptScore W2553001558C143998085 @default.
• W2553001558 hasConceptScore W2553001558C174475383 @default.
• W2553001558 hasConceptScore W2553001558C2483381 @default.
• W2553001558 hasConceptScore W2553001558C2775894508 @default.
• W2553001558 hasConceptScore W2553001558C2778729363 @default.
• W2553001558 hasConceptScore W2553001558C2779282312 @default.
• W2553001558 hasConceptScore W2553001558C2779384505 @default.
• W2553001558 hasConceptScore W2553001558C2780007613 @default.
• W2553001558 hasConceptScore W2553001558C2780817109 @default.
• W2553001558 hasConceptScore W2553001558C28328180 @default.
• W2553001558 hasConceptScore W2553001558C2908722627 @default.
• W2553001558 hasConceptScore W2553001558C2994225774 @default.
• W2553001558 hasConceptScore W2553001558C30481170 @default.
• W2553001558 hasConceptScore W2553001558C45091340 @default.
• W2553001558 hasConceptScore W2553001558C501734568 @default.
• W2553001558 hasConceptScore W2553001558C53226629 @default.
• W2553001558 hasConceptScore W2553001558C54355233 @default.
• W2553001558 hasConceptScore W2553001558C63363279 @default.
• W2553001558 hasConceptScore W2553001558C71924100 @default.
• W2553001558 hasConceptScore W2553001558C86803240 @default.
• W2553001558 hasConceptScore W2553001558C90924648 @default.
• W2553001558 hasLocation W25530015581 @default.

• next